Ginkgo bioworks provides compensation information related to recent acquisitions

Boston , dec. 2, 2022 /prnewswire/ -- ginkgo bioworks holdings, inc. (nyse: dna) ("ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced that in connection with its transaction with bayer cropscience lp ("bayer") on october 17, 2022, ginkgo granted 9,868,143 restricted stock units to 139 new employees, and in connection with its acquisition of zymergen inc. ("zymergen") on october 19, 2022, ginkgo granted 8,305,110 restricted stock units to 179 new employees. the restricted stock units were granted without stockholder approval as material inducements to the employees entering into employment with ginkgo pursuant to nyse listed company manual section 303a.08 and were approved by ginkgo's compensation committee.
DNA Ratings Summary
DNA Quant Ranking